Prolonged inhibition of cholesterol synthesis explains the efficacy of atorvastatin

Journal of Lipid Research

Volumn 38, Issue 7, 1997, Pages 1496-1500

  Naoumova, Rossitza P ^a   Dunn, Stuart ^a   Rallidis, Loukianos ^a   Abu Muhana, Omar ^a   Neuwirth, Clare ^a   Rendell, Nigel B ^a   Taylor, Graham W ^a   Thompson, Gilbert R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

HMG CoA reductase; Low density lipoprotein; Mevalonic acid; Simvastatin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; SIMVASTATIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHOLESTEROL SYNTHESIS; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; ENZYME INHIBITION; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; CHOLESTEROL, LDL; CREATININE; ENZYME INHIBITORS; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; MALE; MEVALONIC ACID; MIDDLE AGED; PYRROLES;

EID: 0030843232     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Shepherd, J., S. M. Cobbe, A. R. Lorimer, J. H. McKillop, I. Ford, C. J. Packard, P. W. MacFarlane, C. Isles, M. F. Oliver, A. F. Lever, B. W. Brown, J. G. G. Ledingham, S. J. Pocock, B. M. Rifkind, B. D. Vallance, D. Ballantyne, L. Anderson, D. Duncan, S. Kean, A. Lawrence, J. Mcgrath, V. Montgomery, J. Norrie, M. Percy, E. Pomphrey, A. Whitehouse, P. Cameron, P. Parker, F. Porteous, L. Fletcher, C. Kilday, D. Shoat, S. Latif, J. Kennedy, M. A. Bell, R. Birrell, M. Mellies, J. Meyer, and W. Campbell. 1996. West of Scotland Coronary Prevention Study: Identification of high risk groups and comparison with other cardiovascular intervention trials. Lancet. 348: 1339-1342.
2. Scandinavian Simvastatin Survival Study Group. 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 344: 1383-1389.
3. Sacks, F. M., M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford, T. G. Cole, L. Brown, J. W. Warnica, J. M. O. Arnold, C. Wun, B. R. Davis, E. Braunwald, and the Cholesterol and Recurrent Events Trial Investigators. 1996. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N. Engl. J. Med. 335: 1001-1009.
4. Thompson, G. R. 1995. Angiographic trials of lipid-lowering therapy: end of an era? Br. Heart J. 74: 343-347.
5. Thompson, G. R., J. Hollyer, and D. D. Waters. 1995. Percentage change rather than plasma level of LDL-cholesterol determines therapeutic response in coronary heart disease. Curr. Opin. Lipidol. 6: 386-388.
6. Thompson, G. R., V. M. Maher, S. Matthews, Y. Kitano, C. Neuwirth, M. B. Shortt, G. Davies, A. Rees, A. Mir, R. J. Prescott, P. de Feyter, and A. Henderson. 1995. Familial Hypercholesterolaemia Regression Study: a randomised trial of low-density-lipoprotein apheresis. Lancet. 345: 811-816.
7. Nawrocki, J. W., S. R. Weiss, M. H. Davidson, D. L. Sprecher, S. L. Schwartz, P. J. Lupien, P. H. Jones, H. E. Haber, and D. M. Black. 1995. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler. Thromb. Vasc. Biol. 15: 678-682.
8. Naoumova, R. P., D. Marais, J. C. Firth, C. K. Y. Neuwirth, G. W. Taylor, and G. R. Thompson. 1996. Atorvastatin augments therapy of homozygous familial hypercholesterolemia by inhibiting up-regulation of cholesterol synthesis after apheresis and bile acid sequestrants. Circulation. 94: I-583.
9. Naoumova, R. P., A. D. Marais, J. Mountney, J. C. Firth, N. B. Rendell, G. W. Taylor, and G. R. Thompson. 1996. Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia. Atherosclerosis. 119: 203-213.
10. Friedewald, W. T., R. I. Levy, and D. S. Fredrickson. 1972. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18: 499-502.
11. Black, D. M. 1995. Atorvastatin: a step ahead for HMG-CoA reductase inhibitors. In Atherosclerosis X. F. P. Woodward, J. Davignon, and A. Sniderman, editors. Elsevier Science Publishers BV, Amsterdam. 307-310.
12. Parker, T. S., D. J. McNamara, C. D. Brown, R. Kolb, E. H. Ahrens, Jr., A. W. Alberts, J. Tobert, J. Chen, and P. J. De Schepper. 1984. Plasma mevalonate as a measure of cholesterol synthesis in man. J. Clin. Invest. 74: 795-804.
13. Yoshida, T., A. Honda, N. Tanaka, Y. Matsuzaki, B. He, T. Osuga, N. Kobayashi, K. Ozawa, and H. Miyazaki. 1993. Simultaneous determination of mevalonate and 7 alpha-hydroxycholesterol in human plasma by gas chromatography-mass spectrometry as indices of cholesterol and bile acid biosynthesis. J. Chromatogr. 613: 185-193.
14. Jones, P. J., A. S. Pappu, D. R. Illingworth, and C. A. Leitch. 1992. Correspondence between plasma mevalonic acid levels and deuterium uptake in measuring human cholesterol synthesis. Eur. J. Clin. Invest. 22: 609-613.
15. McDowell, I. F., G. B. Wisdom, and E. R. Trimble. 1989. Apolipoprotein E phenotype determined by agarose gel electrofocusing and immunoblotting. Clin. Chem. 35: 2070-2073.
16. Thompson, G. R., R. P. Naoumova, and G. F. Watts. 1996. Role of cholesterol in regulating apolipoprotein B secretion by the liver. J. Lipid Res. 37: 439-447.
17. Lindenthal, B., A. Simatupang, M. T. Dotti, A. Federico, D. Lutjohann, and K. Von Bergmann. 1996. Urinary excretion of mevalonic acid as an indicator of cholesterol synthesis. J. Lipid Res. 37: 2193-2201.
18. Saito, Y., S. Yoshida, N. Nakaya, Y. Hata, and Y. Goto. 1991. Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler. Thromb. 11: 816-826.
19. Grundy, S. M. 1988. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N. Engl. J. Med. 319: 24-33.
20. Krause, B. R., and R. S. Newton. 1995. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models. Atherosclerosis. 117: 237-244.
21. Bocan, T. M., E. Ferguson, W. McNally, P. D. Uhlendorf, S. Bak Mueller, P. Dehart, D. R. Sliskovic, B. D. Roth, B. R. Krause, and R. S. Newton. 1992. Hepatic and non-hepatic sterol synthesis and tissue distribution following administration of a liver selective HMG-CoA reductase inhibitor, CI-981: comparison with selected HMG-CoA reductase inhibitors. Biochim. Biophys. Acta. 1123: 133-144.
22. Bakker-Arkema, R. G., M. H. Davidson, R. J. Goldstein, J. Davignon, J. L. Isaacsohn, S. R. Weiss, L. M. Keilson, V. Brown, V. T. Miller, L. J. Shurzinske, and D. M. Black. 1996. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J. Am. Med. Assoc. 275: 128-133.
23. Forster, L. F., G. Stewart, D. K. Bedford, J. P. Stewart, M. J. Caslake, C. J. Packard, J. Shepherd, and D. M. Black. 1996. Stable isotope turnover studies of apolipoprotein B in combined hyperlipidaemia before and after treatment with atorvastatin, a new HMG-CoA reductase inhibitor. Circulation. 94: 1-583.
24. Herd, J. A., C. M. Ballantyne, J. A. Farmer, J. J. Ferguson, K. L. Gould, P. H. Jones, M. S. West, and A. M. Gotto, Jr. 1996. The effect of fluvastatin on coronary atherosclerosis: the Lipoprotein and Coronary Atherosclerosis Study (LCAS). Circulation. 94: I-597.